GILD · News · 20260827N
Regulatory Approval Milestones
GILEAD SCIENCES, INC. · 2026-08-27 · Importance 65 · Surprise 60 · In source text
The U.S. FDA approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single-tablet regimen for virologically suppressed adults with HIV. Bixlenvo is the first and only single-tablet regimen for virologically suppressed patients who are unable to take currently available single-tablet regimens because of complex treatment requirements. The product combines bictegravir, the active backbone of Biktarvy, with lenacapavir, which Gilead is also developing for longer-term HIV treatment and prevention strategies.
Key facts
- The U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg). source
- The U.S. FDA approval of Gilead's once-daily oral combination pill was reported on 2026-08-27. source
- Reuters reported the FDA approved Gilead's once-daily oral combination pill for treatment of adults whose HIV has already been reduced to very low levels.
- Bixlenvo™ is indicated for the treatment of HIV in adults who are virologically suppressed. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | The U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg). |